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King’s College London and Guy’s and St. Thomas’ NHS Foundation Trust, London  
 
 
 
Abstract 
 
Of the many possible hypotheses which explain the recent rise in childhood food allergy, the 
dual allergen exposure hypothesis has been the most extensively investigated. This chapter 
serves as a review and update on the prevention of food allergy, and focuses on recently 
published Randomized Controlled Trials (RCTs) exploring the efficacy of oral tolerance 
induction in infancy for the prevention of food allergy. As a result of these RCTs, National 
Institutes of Health (NIH) recommendations now actively encourage the early introduction of 
peanut for the prevention of peanut allergy and other countries/settings recommend the inclusion 
of potential common food allergens including peanut and egg in complementary feeding 
regimens commencing at approximately 6 months of age, but not before 4 months.1-3 Further 
studies which explore the efficacy of oral tolerance induction to other common food allergens, 
and which focus on optimal timing, duration and adherence are required. 
 
Abbreviations 
CI - Confidence interval 
ITT - Intention-to-treat 
PP – Per Protocol 
SCORAD - SCORing Atopic Dermatitis 
SPT - Skin Prick Test 
LEAP Study - Learning Early About Peanut Allergy Study 
LEAP-On Study - 12 month extension of LEAP Study: Persistence of Oral Tolerance to Peanut 
EAT Study – Enquiring about Tolerance Study. (Randomized Trial of Introduction of Allergenic 
Foods in Breast-Fed Infants) 
HEAP - Hens’ Egg Allergy Prevention  
STAR - Solids Timing for Allergy Research  
STEP - Starting Time for Egg Protein  
BEAT -Beating Egg Allergy  
PETIT - Two-step egg introduction for prevention of egg allergy in high-risk infants with 
eczema 
 
Key words: Food Allergy; Peanut Allergy; Egg Allergy; Allergy prevention.  
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Prevention of food allergy  
 
‘An ounce of prevention is worth a pound of cure’ is an appropriate adage to describe much 
research into food allergy (FA) over the past decade. Given there is currently no cure, research 
has increasingly focused on interventions aimed at FA prevention. These interventions are 
generally applied early in life and include primary prevention, which seeks to prevent the onset 
of IgE sensitization and secondary prevention, which seeks to interrupt the development of FA in 
IgE-sensitized children.  
 
This chapter will discuss possible reasons for the increase in food allergy, review current 
knowledge around methods for primary prevention from recently published research, describe 
statistical issues in FA prevention studies and briefly outline potential directions for future 
research. The main focus will be on lessons learned from the recently published LEAP (Learning 
Early about  Peanut Allergy), LEAP-On (Persistence of Oral Tolerance to Peanut) and EAT 
(Enquiring about Tolerance) randomized controlled trials 4-6 but other published FA prevention 
research is also included.  
Hypothesizing the Increase in Food Allergy 
 
Various hypotheses have been put forward to explain the rise in food allergy. Integration of the 
vitamin D deficiency, hygiene, and dual-allergen exposure hypotheses (which is the focus of this 
chapter) are shown in Figure 1.   
 
This paper focuses on the ‘dual allergen exposure hypothesis’ which suggests that allergic 
sensitization to food occurs through low-dose cutaneous sensitization, whilst early consumption 
of food protein induces oral tolerance.7 This hypothesis was developed following publication of 
studies demonstrating a strong association between dietary exposure, eczema and the 
development of food allergy.  
 
i) Studies demonstrating the role of cutaneous sensitization in FA 
Animal and human observational and in-vitro studies demonstrate transcutaneous sensitization to 
food allergens through inflamed eczematous skin. In humans, the topical application of Arachis 
(peanut) oil onto eczematous skin during infancy was significantly associated with peanut allergy 
in eczematous children.8 Environmental exposure to peanut during infancy (assessed by 
household peanut consumption) increased the risk of peanut allergy; however, if the infant had 
consumed peanut in the first year of life, they were protected against developing peanut allergy.9 
More recent studies found that eczema severity amplifies the risk of peanut sensitization and 
likely allergy resulting from exposure to peanut antigen in household dust.10 A similar increase 
of peanut sensitization and allergy risk was seen in children with filaggrin loss-of-function 
mutations exposed to high levels of peanut allergens in the household dust.11 This provides a 
good example of gene-environment interactions leading to the development of peanut allergy in 
young infants.  
 
A cross-sectional study assessed the route of peanut exposure in the development of allergy and 
captured maternal peanut consumption during pregnancy, breast-feeding, and in the first year of 
life via a questionnaire. Household peanut consumption was also quantified. The median weekly 
household peanut consumption in the patients with PA was significantly increased (18.8 g) 
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compared with control subjects without allergy (6.9 g) and high-risk control subjects (1.9 g).9 
These findings suggest that high levels of environmental exposure to peanut during infancy can 
promote sensitization and support the hypothesis that peanut sensitization occurs due to 
environmental exposure.  
 
ii) Studies demonstrating the role of tolerance induction in early childhood 
An ecological study exploring the prevalence of peanut allergy in infants in Israel compared with 
infants in the UK, found a significantly higher rate in the UK (1.85% vs 0.17%, p<0.001).12 This 
10-fold increase in the prevalence of peanut allergy in UK children remained when confounding 
factors were accounted for. One explanation for this difference is that peanut was introduced at 
an earlier age and consumed in larger quantities in the Israeli infants; 7.1 grams (g) of peanut 
protein per month compared to no exposure (0 g) to peanut protein in children in the UK 
(p<0.001).   
 
The dual allergen exposure hypothesis combines observational data exploring cutaneous 
sensitization and early tolerance induction, and proposes that the balance of exposures during the 
first year of life (depending on whether the initial exposure to peanut is through the skin or gut), 
primes the immune system to develop allergy or tolerance (respectively). A window of 
opportunity exists during the child’s first year of life within which to influence a tolerogenic 
response. The dual allergen exposure hypothesis, predominantly under the guise of oral tolerance 
induction, has been tested in several RCTs which are discussed below.  
Randomized Controlled Trials of Oral Tolerance Induction 
For the purposes of this chapter we consider the use of the term ‘tolerance’ to be a state of 
clinical unresponsiveness to a known allergen. Later in this chapter we discuss the evidence that, 
after oral tolerance induction programs, tolerance may be enjoyed without the need for ongoing 
exposure to that allergen. 
 
a. Peanut allergy 
 
The LEAP study was developed following publication of observational data that early and 
regular consumption of peanuts was associated with the prevention of peanut allergy, particularly 
in children who are at a higher risk due to a compromised skin barrier.11, 12 The LEAP study was 
a randomized controlled trial that assessed oral tolerance induction of peanut in high-risk 
children (severe eczema and/or egg allergic) aged between 4 and 11 months of age in the UK. 
Infants were randomized to consuming peanut products at least 3 times a week (average of 6 g of 
peanut protein a week) or completely avoiding any peanut until 60 months of age.4 LEAP results 
showed that early introduction and regular on-going consumption of peanut resulted in a 
significant reduction in the number of children with peanut allergy at 60 months of age compared 
to those who avoided peanut. The intention-to-treat analysis showed that in the peanut avoidance 
group, 17.2% of the children had challenge-proven peanut allergy at 60 months of age compared 
with 3.2% in the peanut consumption group (81% relative reduction). Furthermore, the LEAP 
study demonstrated both primary and secondary prevention: there was a reduction in peanut 
allergy at 60 months of age in those children who had peanut introduced early, regardless of their 
sensitization status at baseline (based on skin prick test and specific-IgE levels). (Figure 2)  
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Early introduction of peanut was also found to be effective at preventing peanut allergy in a per 
protocol - but not the intention-to-treat (ITT) - analysis of children who participated in the EAT 
study, an RCT in which exclusively breastfed children from the general population were 
randomized to consume peanut (alongside 5 other allergenic foods) from 3 months of age or 
continue exclusive breastfeeding until approximately 6 months after which time parents 
introduced allergenic foods as they wished.6 Children who introduced peanut from 3 months of 
age as per protocol were significantly less likely to develop peanut allergy than those who 
followed United Kingdom Department of Health advice to delay solid food introduction until 
approximately 6 months of age (Per Protocol analysis: 0% vs 2.5%, p=0.003). It is important to 
acknowledge that per-protocol analyses may introduce hidden bias unless the probability of 
receiving the intervention is random with respect to all predictors of a study’s outcome. 
However, an instrumental variable analysis (IVA) of the EAT data showed no evidence that the 
per-protocol estimate of efficacy was biased,13  suggesting that, even in the general population, 
early introduction of peanut is an effective prevention strategy.  
 
In a recently published meta-analysis of oral tolerance induction, Lerokiadonou et al. note 
‘moderate certainty’ of evidence that introducing peanut between 4 and 11 months reduced the 
risk of developing peanut allergy (RR 0.29; 95%CI 0.11–0.74) based on two RCTs (LEAP and 
EAT) investigating early peanut introduction in 1550 children.14  
 
b. Egg allergy  
 
Six RCTs from different countries have now published their findings assessing introduction of 
egg during infancy for the prevention of egg allergy, detailed in Table 1. There is great 
variability in the populations enrolled (high risk vs. population cohorts) and in the form of egg 
used in these studies (ranging from pasteurized raw whole egg to less allergenic extensively 
heated egg) which makes it difficult to compare the findings. Nonetheless there are some 
commonalities between the outcomes of the studies. 
 
Two RCT’s made use of egg sensitization as the primary study outcome; whilst no significant 
effect in egg white specific IgE was noted in HEAP, the BEAT study showed a significant 
difference between groups for egg white SPT.15, 16 Four RCT’s assess egg allergy by oral food 
challenge. No significant difference was noted in the STEP17 or STAR studies (but recruitment 
was discontinued early in STAR).18 The EAT study found a significant difference in egg allergy, 
this was only true for the per protocol population.6 The PETIT study is the only RCT to 
demonstrate a statistically significant lowering of allergy to egg in the ITT analyses.19 In PETIT, 
infants with eczema at age 4–5 months (n = 147) were recruited and assigned to either the 
placebo or intervention group. Uniquely, this trial made use of heated egg powder and extremely 
low starting doses (25 mg of egg protein, equivalent to 0·2 g of whole egg boiled for 15 min). At 
completion, the prevalence of egg allergy (as determined by Oral Food Challenge (OFC) to a 
cumulative dose of 7 g of heated whole egg powder) was significantly lower in the intervention 
group compared to the control group (8 and 38%, respectively, RR 0.22, 95% CI 0.09–0.54, p = 
0.0001). This interim finding prompted an early cessation in enrolment as per the study stopping 
rules. As many of the participants were egg sensitized at baseline, it may well be that this study 
reflects secondary, as opposed to primary prevention of egg allergy.   
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 5
Whilst individual studies may show conflicting or inconclusive results, a meta-analysis by 
Lerokiadonou et al. found ‘moderate certainty’ of evidence that introducing egg between 4 and 6 
months reduced the risk of developing egg allergy (RR 0.56; 95%CI 0.36–0.87) based on five 
RCTs including 1915 children.14  
 
 
c. Other foods – EAT study 
 
The EAT study examined oral tolerance through early introduction of six allergenic foods in over 
1000 exclusively breastfed children.6 In addition to egg and peanut (discussed earlier) the 
intervention group had cow’s milk, wheat, sesame and fish introduced into their diets from 3 
months of age. The control group followed standard UK government advice of exclusively 
breastfeeding until introduction of solid food at approximately 6 months of age. The randomized 
sequence of food introductions for the early introduction group was cow’s milk (yoghurt) first, 
followed by peanut, egg, sesame and whitefish in random order with wheat introduced last. The 
main outcome was a challenge-proven diagnosis of allergy to one or more of the six foods at 1 
year and 3 years of age. In the intention-to-treat (ITT) analysis, 7.1% of the infants in the 
standard group developed food allergy to one or more of the six potentially allergenic foods 
compared with 5.6% in the intervention group (not statistically significant p=0.32). However, in 
the per-protocol analysis, the prevalence of any food allergy was significantly lower in the early-
introduction group compared to the standard-introduction group (2.4% vs 7.3%, p=0.01). The 
risk of having a positive skin prick test (SPT) to any food was 22% lower in the early 
introduction group compared to the standard introduction group at 12 months of age (p=0.07) 
and at 36 months of age (p=0.47). (Primary Outcome Data of the EAT Study is shown in Figure 
3).  
 
In conclusion, RCTs of oral tolerance induction to a range of foods have shown variable results. 
Nonetheless, the finding of ‘moderate certainty” in the meta-analysis, Lerokiadonou et al. for the 
introduction between 4 and 11 months of age for peanut and hens egg is reassuring. 14 Their 
findings for fish and early introduction of milk or hydrolyzed formula were of ‘low certainty’ 
and ‘no evidence’ respectively.  
 
Importantly, both LEAP and EAT demonstrated that the early introduction of allergenic foods 
into the infant’s diet was achievable and safe and that this did not affect breastfeeding rates or 
later nutrition and growth. However, in all studies, adverse event data show that children 
experienced allergic reactions during the initial baseline food challenge and thus, especially in 
high risk populations, children may have pre-existing food allergy despite never having 
knowingly consumed the food.  This is discussed further in the following section exploring 
‘windows of opportunity’ for oral tolerance induction.  
  
Concept of different windows of exposure possibly relating to different foods; age and 
immunological markers 
 
Food allergy typically has its genesis early in infancy, and whilst the age of onset of different 
food allergies is variable, the body of evidence suggests that the pathogenesis of common food 
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allergies starts early in life. Several RCTs examining oral tolerance induction found infants to 
have a high level sensitization or be allergic to the food at baseline and, importantly, before any 
known oral exposure to the food.15, 18 Thus, to maximize the effectiveness of oral tolerance 
induction, it is important to understand the age at which oral tolerance induction programs 
should be commenced.  
 
At inclusion to the EAT study, 5.1% (33/652) of the early introduction group had a positive SPT 
to one of the six allergenic foods being introduced. EAT infants were all enrolled at 3 months of 
age, highlighting that sensitization to foods can begin in very early infancy.6 In the LEAP study, 
76 of the 899 patients screened were excluded from enrolment as they had an SPT of >4mm at 
between 4 and 11 months of age.20 This group was older than those participants who were 
eligible for enrolment to LEAP and who had negative SPT at time of screening (8.3 months of 
age (SD1.88) vs 7.7 months of age (SD 1.74)) and the median peanut SPT wheal diameter in this 
group was suggestive of peanut allergy at 7.5mm (IQR 6.0-9.0).20 Data from LEAP and EAT 
thus suggest that, for oral tolerance to be effective, it should be commenced early, when high 
level sensitization is less likely to have occurred. To this end recently published allergy 
prevention recommendations suggest that introduction is targeted to early infancy but not before 
4 months of age.1-3 However, as demonstrated in EAT, early life dietary interventions present 
logistical challenges as weaning must be balanced with infants’ developmental ability to 
consume solid food. Further studies exploring the effect of age on food allergic sensitization and 
the efficacy of oral tolerance induction in very young infants are needed.  
 
Whilst the evidence suggests that oral tolerance induction may be most effective in very young 
infants who are not yet sensitized to foods, it is also important to understand whether oral 
tolerance induction is effective in children who are already sensitized either because they did not 
introduce allergenic foods in early infancy, or because they became sensitized very early in life. 
The LEAP study excluded children with a skin prick test (SPT) >4mm. This a priori decision 
was based on the assumption that such children would be very likely peanut allergic. Whilst 
including children with larger skin prick tests I  n the study would have been scientifically 
useful, several other studies have shown that using a greater than 4mm cut off as a surrogate 
marker for existing peanut allergy is reasonable regardless of the age or risk profile of the child. 
In the HealthNuts Study around 80% (95% CI, 73.0-87.4) of high-risk infants with an SPT wheal 
size of greater than 4 mm had challenge-confirmed peanut allergy as 12 months of age and the 
Basophil Activation Validation (BAT) Study, found the optimal cut-off for the diagnosis of 
peanut allergy in a UK cohort was greater than 4mm. 21 22 
There is a clear need for robust scientific data assessing the outcome of oral tolerance induction 
in infants who are sensitized (particularly high level sensitized) to food allergens. However, until 
these data are available, current studies suggest that 4mm is an appropriate cut off for clinical 
use.  
 
Issues of dosage 
 
In addition to the window of exposure, the efficacy of oral tolerance induction appears to be 
influenced by the dose of food used. There seems to be a critical level of protein consumption 
required for the development of oral tolerance. In a murine model, a single high dose of peanut 
flour (100 mg) promoted oral tolerance and prevented subsequent IgE sensitization and T-cell 
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proliferation. There is however a paucity of data in the human population as to the optimal 
dosage of an allergenic food protein for the development of long-lived oral tolerance. The LEAP 
Study peanut consumption recommendations were based on the upper quartiles of those noted 
for Israeli infants who appeared to be protected against peanut allergy. 12  In LEAP a dose of 6g 
of peanut protein per week was recommended and on average consumption of 7.1g of peanut 
protein per week was achieved. This LEAP intervention achieved an overall 81% reduction in 
the level of peanut allergy. As adherence was excellent in the LEAP study, it was not possible to 
explore a dose-response relationship but this was explored in the EAT study, where 31.9% of the 
early introduction group were able to adhere, and within those who were non-adherent, the level 
of food-specific adherence in the early consumption group was variable. It is of interest that the 
statistically derived protective level for oral tolerance to peanut in the EAT study mirrors the 
median consumption of peanut protein per week in the Israeli population (1.7g in Israel): 
statistical modeling of EAT data showed that approximately 2g of food protein per week 
protected against both peanut allergy and egg white allergy, reducing the burden of allergic 
disease by approximately 90%. This was also true for protection against developing positive SPT 
to egg white (including SPT to raw egg white). Dose Response Modeling is shown in Figure 4.  
 
Low-level allergen exposure (to select aeroallergens) results in allergic responses whereas high-
level allergen exposure drives tolerance.23, 24 Current data suggest that gram rather than 
milligram doses of food protein will be required for oral tolerance induction, but studies which 
explore the effect of oral tolerance induction with differing doses are required. This is especially 
true in the context of prevention of multiple food allergies where, as seen in EAT, high dose 
consumption of multiple foods may present logistical problems.  
Persistence of Oral Tolerance Induction 
 
Whilst oral tolerance induction has been shown to be effective in preventing food allergy in the 
immediate term, claiming that tolerance, rather than a delay to onset of food allergy, has been 
achieved requires examination of the effects of avoidance of the food under investigation, and/or 
of ad libitum consumption. To date the only food allergy prevention study to address this 
question is the LEAP-On study which examined whether early consumption of peanut had a 
sustained effect on peanut allergy prevention after 12 months of peanut avoidance.5 A total of 
556 participants (88.5% (556/628)) from the original LEAP trial were enrolled in the follow-on 
study. The rate of adherence to avoidance was 90.4% in the peanut-avoidance group and 69.3% 
in the peanut-consumption group. At 72 months of age, peanut allergy remained significantly 
higher in the peanut-avoidance group compared to the peanut-consumption group, 18.6% vs 
4.8% (p<0.001) respectively. The LEAP-On Study showed that the non-allergic status of 
children who had been consuming peanut remained stable over 12 months of subsequent peanut 
avoidance. Thus, the key finding of the two LEAP studies is that early introduction and 
consumption of peanut until 60 months of age causes a reduction in peanut allergy that persists at 
72 months of age after a 12-month period of avoidance. Follow-on studies of the LEAP and EAT 
cohorts are underway to observe whether the effects of early tolerance continue to persist 
approximately seven years after the interventions were stopped and after ad libitum 
consumption. Future studies of oral tolerance induction should include long term follow up after 
ad libitum consumption into their design.  
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Factors affecting adherence 
 
A greater understanding of the many factors that influence adherence are of great clinical and 
public health importance. The lower rate of adherence in the EAT study varied between foods; 
egg ingestion was lower than peanut and milk consumption, but higher than sesame, fish, and 
wheat (which was always the last of the foods to be introduced).6 However, partial adherence 
among early-introduction group participants was not associated with any significant increase in 
allergy prevalence. This offers reassurance that children who are unable to comply with the 
intervention will not increase their risk of food allergy.  
The LEAP study achieved a high adherence rate in the peanut introduction group (92%), 
however frequent contact between study personnel and participating families was built into the 
protocol and peanut introduction was successfully achieved in the LEAP consumption group 
after only a few study contacts.  
There are many other reasons for the differences in adherence rates between LEAP and EAT 
including factors relating to the food’s introduction regimens, and maternal and family factors 
such as education, cultural and ethnic differences. In EAT there was a marked influence of race 
on food allergy rates, being much higher in non-white participants with a stepwise increase from 
white (5.3%), to mixed ethnicity (9.4%), to Asian/black/Chinese participants (19.3%), p<0.0005. 
Conversely, there was a statistically significant stepwise reduction in adherence most notable in 
the early-introduction group with only one in seven Asian/black/Chinese participants adhering to 
the protocol (p=0.01).  
 
Food-allergic children are typically allergic to more than one food however, single allergen oral 
tolerance induction appears to be allergen-specific i.e. early consumption of peanut had no effect 
on development or resolution of other food allergies or atopic diseases.25 Thus, if food allergy 
prevention is to be achieved through early exposure, studies which explore the many factors that 
influence adherence are required so as to maximize the effect of the intervention by promoting 
and facilitating successful introduction of multiple foods in infancy. 
Immunological changes in food allergy prevention  
 
Oral tolerance induction has proven to be successful in achieving clinical tolerance to specific 
foods, suggesting that the dual allergen exposure hypothesis is an accurate representation of one 
of the mechanisms by which food allergy develops. As well as clinical tolerance the LEAP and 
LEAP-On studies have demonstrated immunological changes suggestive of immune tolerance. 
As is now discussed, the dynamics of change are unique to each immune marker.  
 
i) Changes in peanut- SPT, and IgE against peanut and r Ara h 2 
 
In the LEAP study, the mean SPT wheal size was smaller at 60 months of age in the 
consumption group compared with the avoidance group and remained smaller at 72 months of 
age in LEAP-On. In contrast, there was no difference in mean levels of IgE to peanut between 
groups throughout the LEAP study but differences were noted at 72 months of age in LEAP-On 
(lower in the LEAP peanut-consuming population). The mean levels of Ara h 2–specific IgE 
declined significantly in the peanut-consumption group from 30 months to 60 months during 
LEAP (P<0.001) and remained low at 72 months of age in LEAP-On. The inhibition of IgE 
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synthesis is further reflected by the fact that relatively few participants in the peanut-
consumption group had high-level IgE to peanut and to Ara h 2 at 30, 60 and 72 months of age. 
Children who were allergic to peanut at 60 months of age already had higher peanut-specific IgE 
at 12 months, differences remained at 30 and 60 months of age. These findings suggest that the 
elaboration of IgE antibodies to foods occurs early in infancy and may take a very long time to 
switch off, likely due to the presence of long-lived memory B and plasma cells committed to IgE 
production.  
 
ii) Peanut-specific IgG4 and IgG4/IgE changes  
 
Peanut-specific IgG and IgG4 levels increased over time in both LEAP groups, however the 
peanut consumption group, who were largely protected against developing peanut allergy, had a 
significantly greater and earlier increase, which was already evident by 12 months of age. The 
overall balance between peanut-specific IgG4 and peanut-specific IgE reflected the participants’ 
allergic status to peanut. In the LEAP-On study, peanut-specific IgG4 levels and peanut-specific 
IgG4/IgE ratios continued to be higher in the previous peanut consumption group than in the 
previous peanut avoidance group. However, IgG4 levels started to slowly drift down after 30 
months, even in the peanut consumption group. In the participants who became allergic in the 
LEAP-On study (1.1% of the peanut consumption group and 1.1% of the peanut avoidance 
group), the ratio of peanut-specific IgG4/IgE declined between 60 and 72 months. Children from 
the peanut consumption group who were able to tolerate peanut continued to have low levels of 
peanut-specific IgE and high ratios of IgG4/IgE at 60 months in LEAP and this was maintained 
at 72 months. These observations indicate that IgG4 is associated with protection against the 
development of allergy. Peanut-specific IgG4 has recently been shown to inhibit basophil 
activation in vitro in response to peanut. (Figure 5) 
 
Special statistical considerations relating to prevention studies in food allergy  
 
There are critical issues in the design and statistical analyses of prevention studies that differ 
fundamentally from treatment studies.13 For example, in treatment studies all subjects start with 
the disease and few will be cured due to the intervention. In prevention studies all subjects start 
without the disease and, even in high-risk studies such as LEAP, less than 20% will end up with 
the disease. This has two important consequences both with respect to data imputation and with 
respect to analysing changes in biomarkers of prevention.  In treatment studies, an intention to 
treat analysis may impute an allergic outcome to missing data since this is the most likely 
outcome where allergy is assumed to persist unless there is evidence of benefit. However, 
imputing an allergic outcome to all children with missing data in a prevention study could likely 
obscure and severely bias the treatment effect; especially, if the dropout rate is comparable to or 
higher than the disease rate in the population. This difference in prevention studies also affects 
the interpretation of biomarker data. If only a small subgroup of subjects (e.g. 20%) are destined 
to develop the disease, then the immunological effects of a successful intervention may only be 
apparent in this subgroup of 20%. The absence of relevant biomarker changes in the 80% who 
are not destined to develop the disease in the intervention group may obscure or dilute biomarker 
differences between the intervention and controls groups. These problems may be overcome 
using statistical methodologies to control for bias, as recently detailed by H.T. Bahnson et al.13 
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Summary: 
 
Of the many possible hypotheses which explain the recent rise in childhood food allergy, the 
dual allergen exposure hypothesis has been the most extensively investigated. Recently 
published RCTs provide evidence that introduction of peanut (and likely hen’s egg white) in 
early infancy offers a successful strategy for the prevention of food allergy. NIH 
recommendations now actively encourage the early introduction of peanut for the prevention of 
peanut allergy and other countries/settings recommend the inclusion of potential common food 
allergens such as peanut and egg in complementary feeding regimens commencing at around 
approximately 6 months of age, but not before 4 months of age. Further studies which explore 
the efficacy of oral tolerance induction to other common food allergens, and which focus on 
optimal timing, duration and adherence are required.  
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Figures & Tables: 
 
 
 
 
 
Fig 1. Integration of the vitamin D deficiency, hygiene, and dual-allergen exposure 
hypotheses. Sufficient levels of vitamin D, a diverse microbiota, and oral allergen exposure 
collectively support the development of tolerance. Conversely, allergic sensitization is promoted 
through cutaneous exposure, reduced diversity of microbiota, and vitamin D deficiency. 
Diminished microbial diversity and vitamin D deficiency are thought to interrupt the regulatory 
mechanisms of oral tolerance, with the latter also contributing to decreased epidermal barrier 
function. GI, Gastrointestinal; T-reg, regulatory T cells. Graphic modified from Lack G. 
Epidemiologic risks for food allergy. J Allergy Clin Immunol 2008;121:1331-6. Copyright © 
2008 Elsevier. Reprinted with permission. 
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Figure 2. LEAP Study Primary Outcome findings (From Du Toit G, Roberts G, Sayre PH, et 
al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med 
2015; 372:803-13. Copyright © 2015 Massachusetts Medical Society. Reprinted with permission 
from Massachusetts Medical Society) 
 
The prevalence of peanut allergy at 60 months of age is shown among participants who had a 
negative result on the skin-prick test at baseline, among those who had a positive result at 
baseline, and in both groups combined, in the intention-to-treat analysis (Panel A) and the per-
protocol analysis (Panel B). Among the 640 participants who underwent randomization, peanut-
allergy status was determined by means of an oral food challenge in 617 (96.4%) and by means 
of a diagnostic algorithm in 11 (1.7%). Peanut allergy could not be evaluated with the use of the 
diagnostic algorithm in 2 participants (0.3%). A total of 10 participants (1.6%) voluntarily 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 13 
withdrew or were lost to follow-up. The worst-case imputation analysis (Panel C) assumes that 
participants with missing data in the peanut-consumption group would have been allergic to 
peanuts and that participants with missing data in the peanut-avoidance group would have been 
nonallergic. P values are based on chi-square analyses. 
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Figure 3. EAT Study Outcome findings (Perkin MR, Logan K, Tseng A, Raji B, Ayis S, 
Peacock J, et al. Randomized Trial of Introduction of Allergenic Foods in Breast-Fed Infants. N 
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Engl J Med 2016. Copyright © 2016 Massachusetts Medical Society. Reprinted with permission 
from Massachusetts Medical Society) 
 
The prevalence of IgE-mediated food allergy is shown with respect to one or more of the six 
early-intervention foods (peanut, cooked egg, cow’s milk, sesame, whitefish, and wheat; Panel 
A), to peanut (Panel B), and to egg (Panel C).  The first column shows the intention-to-treat 
analysis, the second column the per-protocol analysis, and the third column an adjusted per-
protocol analysis. The intention-to-treat analysis included all the participants who had data that 
could be evaluated; the per-protocol population included all participants who adhered adequately 
to the assigned regimen. The adjusted per-protocol analysis was a conservative per-protocol 
analysis that adjusted the prevalence of food allergy in the standard-introduction group by 
subtracting the number of participants in the early-introduction group who had a positive result 
on the challenge at enrollment and who completed the trial with a confirmed food allergy from 
both the numerator (the number of participants with allergy in the standard-introduction group) 
and the denominator (the number of participants in the standard introduction 
group who adhered to the protocol). P values are based on chi-square analyses or Fisher’s exact 
test, as appropriate.  
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Figure 4. EAT Dose–Response Analysis of the Relationship between Mean Weekly Dose of 
Peanut or Egg Protein Consumed and Allergy or Positive Result on Skin-Prick Testing to 
Peanut, Egg, and Raw Egg White (Perkin MR, Logan K, Tseng A, Raji B, Ayis S, Peacock J, 
et al. Randomized Trial of Introduction of Allergenic Foods in Breast-Fed Infants. N Engl J Med 
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2016. Copyright © 2016 Massachusetts Medical Society. Reprinted with permission from 
Massachusetts Medical Society) 
 
Shown are the predictive probability plots that were generated from statistical models of the 
prevalence of peanut allergy and egg allergy (Panel A) and of a positive result on skin-prick 
testing to peanut and egg at 12 months (Panel B) and to peanut, egg, and raw egg white at 36 
months (Panel C), according to the mean weekly consumption of peanut and egg protein between 
enrollment and 6 months of age. The prevalence of both food allergy and positive skin-prick test 
diminishes with increasing levels of mean weekly consumption. Insets show the same data on an 
enlarged y axis 
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Figure 5. Changes that occur with IgE, IgG and IgE:IgG4 ratios over time ii children who 
consumed or avoided peanuts in the frame of the LEAP and LEAP-On studies (Du Toit G, 
Sayre PH, Roberts G, Sever ML, Lawson K, Bahnson HT, et al. Effect of Avoidance on Peanut 
Allergy after Early Peanut Consumption. N Engl J Med 2016; 374:1435-43. Copyright © 2016 
Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society) 
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Name of Trial Country Type Population Intervention group 
(hen's egg protein 
per week) 
Control group N Intervention 
period  
(age in 
months) 
Outcome 
assessed 
(age in 
months) 
Primary 
outcome  
Outcome in ITT  
(p value) 
Enquiring About Tolerance 
(EAT) 
UK  RCT, open 
label  
general 
population 
cooked whole HE 
(4g) 
HE avoidance 
until 6 months of 
age 
1303 3-6 12-36 HE allergy (OFC)  RR 0.69  
(95% CI 0.40-
1.18) 
(p= 0.17) 
Hens’ Egg Allergy 
Prevention (HEAP) 
Germany  RCT, blinded  general 
population 
pasteurised raw HE 
white powder 
(7.5g) 
HE free diet 
placebo powder 
(rice) 
HE free diet 
298 4-12 12 HE sensitisation 
(sIgE)  
 
RR 2.20  
(95% CI 0.68-
7.14)  
(p=0.24) 
Solids Timing for Allergy 
Research (STAR) 
Australia  RCT, blinded high risk  
(infants with 
moderate/severe 
eczema) 
pasteurised raw 
whole HE powder 
(6.3g) 
placebo powder 
(rice) 
86 0-8 12 raw HE allergy 
(OFC) and 
Sensitisation 
(SPT) 
RR 0.65 
(95% CI 0.38-
1.11) 
(p=0 .11) 
Starting Time for Egg 
Protein (STEP) 
Australia  RCT, blinded moderate risk 
(atopic mothers) 
pasteurised raw 
whole HE powder 
(2.8g) 
placebo powder 
(rice) 
820 4-10 12 raw HE allergy 
(OFC) and 
Sensitisation 
(sIgE) 
Adj RR 0.75 
(95% CI 
0.48-1.17 
(p=0.20) 
Beating Egg Allergy (BEAT) Australia  RCT, blinded moderate risk  
(1
st
 degree 
relative with 
allergy) 
pasteurised raw 
whole HE powder 
(2.45g)  
HE free diet 
placebo powder 
(rice) 
HE free diet 
254 4-8 12 HE sensitisation 
(SPT)  
OR 0.46 
(95% CI 0.22-
0.95)  
(p=0.03) 
Two-step egg introduction 
for prevention of egg 
allergy in 
high-risk infants with 
eczema (PETIT) 
Japan RCT, blinded moderate risk  
(with atopic 
dermatitis) 
heated HE powder 
(0.175g for 3 
months then 
0.875g for 3 
months) 
placebo powder 
(squash)  
121 4-12 12 HE allergy (OFC)  RR 0·222 
(95% CI 0·08–
0·61) 
(p=0·0012) 
 
Table 1. Summary of Randomized Controlled Trials with Hens Egg. ITT – Intention to treat. RR – Relative Risk. OR – Odds Ratio 
